Cargando…

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation

Hereditary transthyretin‐mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long‐standing treatment. However, disease progression continues post‐LT. This Phase 3b, open‐label trial evaluated efficacy and safety of patisiran i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Hartmut H., Wixner, Jonas, Planté‐Bordeneuve, Violaine, Muñoz‐Beamud, Francisco, Lladó, Laura, Gillmore, Julian D., Mazzeo, Anna, Li, Xingyu, Arum, Seth, Jay, Patrick Y., Adams, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310767/ https://www.ncbi.nlm.nih.gov/pubmed/35213769 http://dx.doi.org/10.1111/ajt.17009

Ejemplares similares

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Non-parametric estimation of survival in age-dependent genetic disease and application to the transthyretin-related hereditary amyloidosis
por: Alarcon, Flora, et al.
Publicado: (2018)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs
por: Norgren, Nina, et al.
Publicado: (2014)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2019)

Delayed small bowel octreotide response in patients with hereditary transthyretin amyloidosis
por: Jonas, Wixner, et al.
Publicado: (2015)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis
por: Wixner, Jonas, et al.
Publicado: (2013)

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2020)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
por: Dispenzieri, Angela, et al.
Publicado: (2022)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
por: Skrahina, Volha, et al.
Publicado: (2021)

Outcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis
por: Wixner, Jonas, et al.
Publicado: (2015)

Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy
por: Wixner, J, et al.
Publicado: (2012)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients
por: Wange, Niklas, et al.
Publicado: (2018)

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2020)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Gentile, Luca, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
por: Inês, Mónica, et al.
Publicado: (2020)

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2022)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4hg7j506kh2vpvk5h3eltkbrr1